STICHTING OOGZIEKENHUIS ROTTERDAM

Their core work

Rotterdam Eye Hospital (Oogziekenhuis Rotterdam) is a specialist ophthalmic hospital in the Netherlands that combines patient care with clinical research in ophthalmology. In H2020 projects, they contribute as a clinical site — providing access to patient cohorts with rare retinal diseases, clinical trial infrastructure, and disease-specific diagnostic and surgical expertise. Their research participation spans both the engineering side of eye care (robotic micro-surgery) and the genetic medicine side (AAV-based gene therapy for inherited retinal degeneration). For consortium partners, they are the bridge between laboratory science and real patients with rare eye conditions.

What they specialise in

How they've shifted over time

In the 2015–2018 period their H2020 engagement was in digital health technology — specifically robotics applied to ophthalmic micro-surgery, with no disease-area keywords attached. From 2018 onward the focus shifted sharply to rare disease genetics: retinitis pigmentosa, Usher syndrome, gene therapy, and dual AAV vectors dominate their recent profile. This is a meaningful pivot from enabling technology (better surgical tools) toward disease-modifying medicine (genetic correction of inherited blindness), reflecting a broader field-wide shift in ophthalmology research priorities toward gene and cell therapy.

Their trajectory points firmly toward becoming a specialist clinical partner for ocular gene and cell therapy trials, particularly for rare inherited retinal diseases where access to well-characterized patient cohorts is the critical bottleneck for academic and biotech sponsors.

How they like to work

Rotterdam Eye Hospital has participated exclusively as a consortium partner — they have never led an H2020 project. This is consistent with their role as a clinical site that enables research designed by academic or technology-focused coordinators. With 18 unique partners across just 2 projects, they operate within mid-sized international consortia rather than small bilateral arrangements. Working with them means gaining access to a clinical partner that brings the patients, the diagnostic infrastructure, and the ophthalmology domain knowledge — not a coordinator that will manage the project.

Their two projects have connected them to 18 distinct consortium partners across 8 countries, indicating solid European reach for an organization with only 2 funded projects. The network spans both technology partners (robotics, EurEyeCase) and biomedical research groups (gene therapy, UshTher), suggesting they are recognized across different communities within ophthalmology research.

What sets them apart

Rotterdam Eye Hospital is one of the Netherlands' dedicated specialist eye hospitals with an active research arm, making it relatively rare as a clinical partner that can offer both surgical expertise and rare disease patient access within a single institution. Their dual track record — surgical technology and genetic medicine — means they can contribute meaningfully to consortia from very different angles, depending on the research question. For anyone developing ophthalmic gene therapies or surgical tools who needs a clinical validation site with established patient cohorts for conditions like Usher syndrome, they are a direct-access partner rather than a referral hub.

Highlights from their portfolio

• UshTher
  A rare-disease gene therapy clinical trial using dual AAV vectors — a technically demanding delivery approach for a large therapeutic gene — targeting Usher syndrome patients, placing this hospital at the forefront of ocular genetic medicine.
• EurEyeCase
  Their entry into H2020 as a clinical use-case partner for European surgical robotics, demonstrating early willingness to test emerging technologies in live ophthalmic procedures.